Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Sara Duckworth Harward"'
Autor:
Geraldine Ferron-Brady, Naomi B. Haas, Sophie Cousin, Christopher L. Carpenter, Christopher A. French, Meg Annan, Victor Moreno, David S. Hong, Peter J. O'Dwyer, Anastasia Wyce, Rabinder K Prinjha, Nigel J. Parr, Irene Brana, Christine L. Hann, Arindam Dhar, Yuehui Wu, Sarina Anne Piha-Paul, P. A. Cassier, Olena Barbash, Johann S. de Bono, John Hilton, Thierry Horner, Sara Duckworth Harward, Mark C. Markowski, Geoffrey I. Shapiro
Publikováno v:
Scientia
JNCI Cancer Spectrum
JNCI Cancer Spectrum
Carcinoma; Concentració de fàrmac en plasma; Farmacocinètica Carcinoma; Concentración de fármaco en plasma; Farmacocinética Carcinoma; Plasma drug concentration; Pharmacokinetics Background Bromodomain and extra-terminal domain proteins are pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66fb87fbe738f6db9e9cf6ed5c983def
https://doi.org/10.1093/jncics/pkz093
https://doi.org/10.1093/jncics/pkz093
Autor:
Jianfeng Xu, Anita Scribner, Brian A. Johns, Mark Johnson, Jerry Jeffrey, Viviana Wilches, Moti Ramgopal, Edwin DeJesus, Franco Felizarta, Christine L. Talarico, Jianjun Gan, Paul M. Benson, Roxanne C. Jewell, Etienne Dumont, Fiona Halliday, Sara Duckworth Harward
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 71(5)
Background GSK2838232 is a second-generation, potent, small-molecule, oral human immunodeficiency virus type 1 (HIV-1) maturation inhibitor for once-daily administration boosted with a pharmacoenhancer. Methods The phase 2a, proof-of-concept study wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::379ba8f6e89f8981a98d23226af0f9ce
https://pubmed.ncbi.nlm.nih.gov/31769793
https://pubmed.ncbi.nlm.nih.gov/31769793